Swiss biotech firm Lonza will add three more production lines to its site in Visp, southwestern Switzerland, to manufacture an active ingredient for the Moderna vaccine, as part of a larger effort ...

Lonza has boosted its ability to cater for customers in the fast-emerging antibody-drug conjugate category with a deal to buy Dutch company Synaffix and its platform technology for designing and ...

Roche is set to raise $1.2 billion from the sale of a US biologics manufacturing facility to Swiss contract development and manufacturing organisation (CDMO) Lonza, part of a drive to match ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

(RTTNews) - Lonza Group (LZAGF.PK), a Swiss manufacturer focused on the pharmaceutical and nutrition businesses, on Thursday reported that its third-quarter performance was in line to deliver on ...

Lonza, announced it has completed its acquisition of the Genentech large-scale biologics manufacturing site in Vacaville, California (US) from Roche for USD 1.2 billion. The Vacaville facility ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Key players like Lonza, ACG, and Capsugel are focusing on expanding production capabilities to meet growing demand, with North America leading the market in 2023 and the Asia Pacific region ...

Figures prepared in accordance with International Accounting Standards. Market value as of Oct. 23, 2023. © 2024 Fortune Media IP Limited. All Rights Reserved. Use ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...